A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry.

IF 1.3 Q4 RHEUMATOLOGY
Fatoş Önen, Gerçek Can, Sedat Çapar, Ediz Dalkılıç, Yavuz Pehlivan, Soner Şenel, Servet Akar, Süleyman Serdar Koca, Abdurrahman Tufan, Ayten Yazıcı, Sema Yılmaz, Nevsun İnanç, İsmail Sarı, Merih Birlik, Dilek Solmaz, Ayşe Cefle, Mehmet Akif Öztürk, Servet Yolbaş, Niels Steen Krogh, Neslihan Yılmaz, Şükran Erten, Cemal Bes, Özgül Soysal Gündüz, Berna Göker, Seminur Haznedaroğlu, Şule Yavuz, Gözde Yildirim Çetin, Fatih Yıldız, Haner Direskeneli, Nurullah Akkoç
{"title":"A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry.","authors":"Fatoş Önen,&nbsp;Gerçek Can,&nbsp;Sedat Çapar,&nbsp;Ediz Dalkılıç,&nbsp;Yavuz Pehlivan,&nbsp;Soner Şenel,&nbsp;Servet Akar,&nbsp;Süleyman Serdar Koca,&nbsp;Abdurrahman Tufan,&nbsp;Ayten Yazıcı,&nbsp;Sema Yılmaz,&nbsp;Nevsun İnanç,&nbsp;İsmail Sarı,&nbsp;Merih Birlik,&nbsp;Dilek Solmaz,&nbsp;Ayşe Cefle,&nbsp;Mehmet Akif Öztürk,&nbsp;Servet Yolbaş,&nbsp;Niels Steen Krogh,&nbsp;Neslihan Yılmaz,&nbsp;Şükran Erten,&nbsp;Cemal Bes,&nbsp;Özgül Soysal Gündüz,&nbsp;Berna Göker,&nbsp;Seminur Haznedaroğlu,&nbsp;Şule Yavuz,&nbsp;Gözde Yildirim Çetin,&nbsp;Fatih Yıldız,&nbsp;Haner Direskeneli,&nbsp;Nurullah Akkoç","doi":"10.5152/eurjrheum.2022.21060","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey. This study aimed to provide an overview of TURKBIO data collected by June 2018.</p><p><strong>Methods: </strong>The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Demographic and clinical features, disease activity markers, and other follow-up parameters, current and previous treat- ments, and adverse events were registered electronically at each visit using open-source software. The registration of patient-reported outcome measures was carried out electronically by the patients using touch screens.</p><p><strong>Results: </strong>TURKBIO registry included a total of 41,145 treatment series with biologicals. There were 2,588 patients with axSpA (2,459 AS and 129 nr-axSpA), 2,036 with RA, and 428 with PsA. The total number of patients, including those with other diagnoses, was 5,718. In the follow-up period, the number of patients and also visits steadily increased by years. The yearly mean number of visits per patient was found to be 2.3. Significant improvements in disease activity and health assessment parameters were observed following the biological treatments. Biologics were often given in combination with a con- ventional synthetic disease-modifying antirheumatic drug in patients with RA. Infections were the most commonly seen adverse events, followed by allergic reactions. Tuberculosis was observed in 12 patients, malignancy in 18, and treatment-related mortality in 31.</p><p><strong>Conclusion: </strong>TURKBIO provided a valuable real-life experience with the use of biologics in rheumatic diseases in Turkey.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"9 2","pages":"82-87"},"PeriodicalIF":1.3000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/40/02/ejr-9-2-82.PMC10176217.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/eurjrheum.2022.21060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 3

Abstract

Objective: TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey. This study aimed to provide an overview of TURKBIO data collected by June 2018.

Methods: The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Demographic and clinical features, disease activity markers, and other follow-up parameters, current and previous treat- ments, and adverse events were registered electronically at each visit using open-source software. The registration of patient-reported outcome measures was carried out electronically by the patients using touch screens.

Results: TURKBIO registry included a total of 41,145 treatment series with biologicals. There were 2,588 patients with axSpA (2,459 AS and 129 nr-axSpA), 2,036 with RA, and 428 with PsA. The total number of patients, including those with other diagnoses, was 5,718. In the follow-up period, the number of patients and also visits steadily increased by years. The yearly mean number of visits per patient was found to be 2.3. Significant improvements in disease activity and health assessment parameters were observed following the biological treatments. Biologics were often given in combination with a con- ventional synthetic disease-modifying antirheumatic drug in patients with RA. Infections were the most commonly seen adverse events, followed by allergic reactions. Tuberculosis was observed in 12 patients, malignancy in 18, and treatment-related mortality in 31.

Conclusion: TURKBIO provided a valuable real-life experience with the use of biologics in rheumatic diseases in Turkey.

Abstract Image

Abstract Image

Abstract Image

风湿病患者生物治疗的现实分析:来自TURKBIO登记处的数据。
TURKBIO登记处成立于2011年,是土耳其第一个全国性的生物数据库。本研究旨在提供截至2018年6月收集的TURKBIO数据的概述。方法:登记包括类风湿关节炎(RA),强直性脊柱炎(AS),非放射性轴性脊柱炎(nr-AxSpA)和银屑病关节炎(PsA)的成年患者。人口统计学和临床特征、疾病活动标志物和其他随访参数、当前和以前的治疗以及不良事件在每次就诊时使用开源软件进行电子登记。患者报告的结果测量的登记由患者使用触摸屏进行电子登记。TURKBIO注册表共包括41,145个生物制剂治疗系列。有2588例axSpA患者(2459例AS和129例nr-axSpA), 2036例RA和428例PsA。包括其他诊断在内的患者总数为5718人。在随访期间,患者数量和访问量逐年稳步增加。每位患者的年平均就诊次数为2.3次。生物治疗后,疾病活动性和健康评估参数显著改善。在RA患者中,生物制剂通常与传统的合成疾病改善抗风湿药物联合使用。感染是最常见的不良反应,其次是过敏反应。结核病12例,恶性肿瘤18例,治疗相关死亡31例。结论:TURKBIO为土耳其风湿病患者使用生物制剂提供了宝贵的现实经验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
56
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信